# Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

> **NCT07185815** · PHASE1,PHASE2 · RECRUITING · sponsor: **Mapi Pharma Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Schizophrenia
- Bipolar I Disorder
- Major Depressive Disorder

## Interventions

- **DRUG:** Cariprazine Depot
- **DRUG:** Cariprazine Depot
- **DRUG:** Cariprazine Depot MTD
- **DRUG:** Oral Cariprazine 3 mg/day

## Key facts

- **NCT ID:** NCT07185815
- **Lead sponsor:** Mapi Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185815, "Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07185815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*